| 0.9 -0.01 (-1.1%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.11  |
1-year : | 1.29 |
| Resists | First : | 0.95 |
Second : | 1.11 |
| Pivot price | 0.87 |
|||
| Supports | First : | 0.69 | Second : | 0.57 |
| MAs | MA(5) : | 0.89  |
MA(20) : | 0.91 |
| MA(100) : | 1.22 |
MA(250) : | 1.16 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.9 |
D(3) : | 53.1 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 1.79 | Low : | 0.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FEMY ] has closed below upper band by 40.9%. Bollinger Bands are 10% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.94 | 0.94 - 0.94 |
| Low: | 0.89 - 0.89 | 0.89 - 0.9 |
| Close: | 0.89 - 0.9 | 0.9 - 0.91 |
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Tue, 17 Jun 2025
Femasys (FEMY) Appoints Kelley Nicholas as Chief Commercial Officer | FEMY Stock News - GuruFocus
Tue, 17 Jun 2025
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth - Stock Titan
Thu, 12 Jun 2025
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates - MSN
Wed, 11 Jun 2025
Femasys (FEMY): Buy Rating Reiterated by HC Wainwright & Co. | FEMY Stock News - GuruFocus
Wed, 11 Jun 2025
Femasys Announces Partnership with Carolinas Fertility - GlobeNewswire
Fri, 30 May 2025
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.436e+007 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 852 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.947e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 600.1 % |
| Return on Equity (ttm) | -65.7 % |
| Qtrly Rev. Growth | 1.7e+006 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 15.04 |
| Price to Cash Flow | -33.56 |
| Dividend | 0 |
| Forward Dividend | 799300 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|